First, there is a lack of robust, prospective data evaluating the long-term effectiveness of cancer screening, vaccinations, and IVIG replacement in patients with CLL and also in patients with CLL receiving targeted therapies such as BTK or BCL-2 inhibitors. This evidence concerns the gene BTK and cancer.